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BACKGROUND & AIMS: Patients with cirrhosis and variceal
hemorrhage have a high risk of rebleeding. We performed a
prospective randomized trial to compare the prevention of
rebleeding in patients given a small-diameter covered stent vs
those given hepatic venous pressure gradient (HVPG)-based
medical therapy prophylaxis. METHODS: We performed an
open-label study of patients with cirrhosis (92% Child class A
or B, 70% alcoholic) treated at 10 medical centers in Germany.
Patients were assigned randomly more than 5 days after vari-
ceal hemorrhage to groups given a small covered transjugular
intrahepatic portosystemic stent-shunt (TIPS) (8 mm; n ¼ 90),
or medical reduction of portal pressure (propranolol and iso-
sorbide-5-mononitrate; n ¼ 95). HVPG was determined at the
time patients were assigned to groups (baseline) and 2 weeks
later. In the medical group, patients with an adequate reduction
in HVPG (responders) remained on the drugs whereas non-
responders underwent only variceal band ligation. The study
was closed 10 months after the last patient was assigned to a
group. The primary end point was variceal rebleeding. Survival,
safety (adverse events), and quality of life (based on the Short
Form–36 health survey) were secondary outcome measures.
RESULTS: A signiﬁcantly smaller proportion of patients in the
TIPS group had rebleeding within 2 years (7%) than in the
medical group (26%) (P ¼ .002). A slightly higher proportion of
patients in the TIPS group experienced adverse events,
including encephalopathy (18% vs 8% for medical treatment;
P ¼ .05). Rebleeding occurred in 6 of 23 patients (26%)
receiving medical treatment before hemodynamic control was
possible. Per-protocol analysis showed that rebleeding
occurred in a smaller proportion of the 32 responders (18%)
than in nonresponders who received variceal band ligation
(31%) (P ¼ .06). Fifteen patients from the medical group (16%)
underwent TIPS placement during follow-up evaluation, mainlyfor refractory ascites. Survival time and quality of life did not
differ between both randomized groups. CONCLUSIONS:
Placement of a small-diameter, covered TIPS was straightfor-
ward and prevented variceal rebleeding in patients with Child
A or B cirrhosis more effectively than drugs, which often
required step-by-step therapy. However, TIPS did not increase
survival time or quality of life and produced slightly more
adverse events. Clinical Trial no: ISRCTN 16334693.Keywords: Nonselective b-Blocker; HVPG; TIPS; Advanced Liver
Disease.
ariceal bleeding is a major complication ofVcirrhosis, associated with a hospital mortality rate
of 10%–20%.1–3 Overall mortality may be higher owing to
deaths before admission.4 Surviving patients are at high
risk for recurrent hemorrhage, which is decreased by
nonselective b-blockers (NSBBs) with or without
nitrates,5–7 ligation of varices, mostly combined with
NSBBs,8,9 or placement of a transjugular intrahepatic por-
tosystemic stent-shunt (TIPS). TIPS is the most effective
method to prevent rebleeding,10 however, it is burdened
with increased hepatic encephalopathy and deterioration
of liver function in patients with advanced cirrhosis.11
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was shown that TIPS placement within 72 hours after
acute bleeding not only prevented recurrent bleeding but
also improved survival.12 This raises the question of
whether ligation together with NSBB should remain the
ﬁrst choice for elective secondary prophylaxis.13–15 NSBBs
require lifelong treatment16 and almost one third of pa-
tients have contraindications, side effects, or are non-
compliant.4 Patients with insufﬁcient portal pressure
reduction (<20%) assessed by measuring hepatic venous
pressure gradient (HVPG) have a high rebleeding risk
without further prophylaxis.17–20 This challenges the
rationale of drug treatment in these patients.
One trial compared the most potent combination of drug
therapy (propranolol plus isosorbide-5-mononitrate) with
an uncovered 10-mm TIPS after the ﬁrst episode of variceal
bleeding. TIPS was signiﬁcantly more potent in the pre-
vention of rebleeding but had an encephalopathy rate of
nearly 40%.21 Therefore, we examined whether 8-mm
covered TIPS (cTIPS) is superior to a hemodynamically
tailored rebleeding prophylaxis in patients with moderately
decompensated cirrhosis. Patients with an insufﬁcient
decrease of HVPG underwent ligation of esophageal varices
and drugs were stopped.Patients and Methods
Study Design
This was an open-label, randomized, multicenter trial
comparing TIPS (group A) with HVPG-guided drug application
(group B) for prophylaxis of rebleeding from varices in patients
with cirrhosis 5–21 days (stratum I) or more than 3 weeks
(stratum II) after standard treatment of a variceal hemorrhage,
using ligation, vasoactive therapy, and antibiotics. Treatment
was initiated as soon as possible after randomization. Patients
in group B were scheduled to receive 2 HVPG measurements. If
they were found to be nonresponders they were switched to
ligation only. The responders (decrease of portal pressure of
20% or greater or to less than 12 mm Hg at 2 weeks after a full
dose of propranolol/nitrate) remained on the titrated medica-
tion without ligation.Randomization
After veriﬁcation of inclusion and exclusion criteria the
patients were assigned (1:1) into group A or group B by fax
randomization following a block randomization scheme strati-
fying for centers and time after index bleed (strata). The
scheme was generated at the Institut für Medizinische Bio-
metrie, Informatik und Epidemiologie, University of Bonn. For
allocation concealment, assignment to the respective group was
performed by independent uninvolved individuals.Participating Centers
Ten centers participated. Eligibility criteria were as follows:
a high level of experience with cirrhosis, TIPS placement,
endoscopic ligation, medical decompressive therapy, and
adequate facilities for clinical trials. All co-authors had access to
the study data and reviewed and approved the ﬁnal manuscript.Inclusion and Exclusion Criteria
Patients had to fulﬁll the following inclusion criteria:
cirrhosis (histologic or clinical), Child–Pugh score22 less
than 12, bilirubin level of 3 mg/dL or less (51.3 umol/L), sig-
niﬁcant variceal bleeding more than 5 days before randomi-
zation, 2 or more esophageal varices, age 18–75 years, and
written informed consent signed and dated by the investigator.
Exclusion criteria were as follows: overt hepatic encephalop-
athy, prehepatic portal hypertension, type II gastric varices as
exclusive bleeding site, chronic drug treatment of portal hyper-
tension with b-blockers and/or nitrates, listing for liver trans-
plantation on T2 status or a highmodel for end-stage liver disease
score (>30) at randomization, existing portosystemic shunt, heart
failure greater than New York Heart Association 2, ejection frac-
tion less than 40%, contraindication against propranolol or ni-
trates, platelet count less than 30 G/L, prothrombin index less
than 30%, disseminated intravascular coagulation, advanced
malignancy, severe infection, female patients of child-bearing
potential not using contraceptive measures during the study, or
female patients with a positive pregnancy test or nursing women.
Interventions
In general, group A received an 8-mm polytetraﬂuoro-
ethylene graft-lined TIPS (Gore Viatorr) insertion. In 5 (6%) of
the 88 per-protocol group A patients, 8mm cTIPS was not
feasible. Instead, they received a 10-mm stent but were not
excluded. During this procedure, HVPG and the gradient be-
tween the portal pressure and inferior vena cava were assessed
before and immediately after TIPS.
After assessment of baseline HVPG as described thor-
oughly,23 group B received propranolol starting at 40 mg twice
daily. Dosage was increased by 10 mg twice daily until a 25%
reduction of basal heart rate occurred or the maximum toler-
ated dose was reached. After successful titration, isosorbide-5-
mononitrate (20 mg twice daily) was added. After a 2-week
intake of the established medication, response was assessed
by a second HVPG measurement in the morning before drug
intake. Responders remained on drugs only and nonresponders
were switched to ligation only.
In case of bleeding, the patients received standard treat-
ment (endoscopic hemostasis, vasoactive drugs, antibiotics),
with further therapy according to their physician’s discretion.
TIPS revision was performed according to the physician’s
judgment at the individual center, mainly on the basis of follow-
up ultrasound (signiﬁcant decrease of portal venous blood ﬂow)
and/or endoscopic examinations (recurrence of large varices).
Endoscopic band ligation was performed with a 6-shooter
multiband device and repeated in case of recurrence of large
varices.
Follow-up Evaluation, Documentation,
and Monitoring
Regular follow-up visits were scheduled on days 14, 90,
180, and thereafter every 6 months with the following assess-
ments to be performed: physical examination, medication
check, electrocardiography, encephalopathy score (West Haven
criteria), Child–Pugh and model for end-stage liver disease
scores, quality of life (Short Form–36 [SF-36]), laboratory
values, Doppler sonography to monitor TIPS function, or
endoscopy for the ligation patients.
Table 1.Baseline Characteristics of the Patients: Group A:
TIPS, Group B: Drugs/Ligation
Group A
(n ¼ 90)
Group B
(n ¼ 95)
Male 69% 66%
Alcoholic cirrhosis 67% 74%
Age, mean ± SD, y 55.4 ± 9.8 54.5 ± 9.7
Varices with red color sign 51% 49%
Hemoglobin level, g/dL 11 ± 2.0 10 ± 1.7
Hemoglobin level, mmol/L 6.8 ± 1.2 6.4 ± 1.0
Platelets, G/L 130 ± 74 134 ± 86
Ascites 48% 55%
Bilirubin level, mg/dL 1.4 ± 0.7 1.5 ± 0.8
Bilirubin level, umol/L 23 ± 12 26 ± 13
Sodium level, mmol/L 138 ± 3.3 138 ± 3.6
INR 1.3 ± 0.2 1.2 ± 0.2
Creatinine level, mg/dL 0.9 ± 0.6 0.9 ± 0.6
Creatinine level, mmol/L 82 ± 51 83 ± 50
Child–Pugh score 6.9 ± 1.5 7.0 ± 1.7
Child A 45% 49%
MELD score 10 ± 2.8 10 ± 3.4
Portal pressure
(HVPG), mm Hg
20.4 ± 5.6 20.5 ± 6.1
Stratum I/II 57%/43% 56%/44%
INR, international normalized ratio; MELD, model for end-
stage liver disease.
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regular on-site visits.
Outcome Measures
The primary objective was time to signiﬁcant rebleeding as
deﬁned by Baveno III24 (ie, hematemesis or melena together
with >2 U of blood within 48 hours of time 0 plus a systolic
pressure <100 mm Hg or a postural change >20 mm Hg or a
pulse rate >100/min at time 0). The bleeding site had to
be conﬁrmed by endoscopy whenever possible. Secondary
objectives were as follows: overall survival, safety (serious
adverse events categorized according to system organ classes
by MedDRAV17.0, follow-up evaluation of liver values), and
quality of life assessed by the SF-36 health survey.25 The pre-
deﬁned outcomes were assessed at the trial sites and were
controlled by monitors. In case of liver transplantation patients
were censored on the day of the procedure with the exception
of 1 patient who died during surgery.
Sample Size Calculation
Assuming that 10% of the medical responders19,26 and 40%
of the nonresponders allocated to ligation would have a
rebleeding event and that half of the patients would be re-
sponders,27 we expected rebleeding rates of 25% in group B
and of 10% in group A10,11 within an 18-month follow-up
period. Anticipating a recruitment time of 3 years a sample
size of 79 patients per group was calculated28 to show a power
of 90% (type I error rate 5%, 2-sided). Additional simulations
taking into account the heterogeneity of the rebleeding risk in
group B and a drop-out rate of 10% suggested a sample size of
93 patients per group.
Statistical Analysis
For quantitative variables, the mean, SD, median, minimum,
and maximum values were reported. For qualitative variables
frequencies are shown. Analyses of clinical characteristics,
rebleeding, hemorrhage-free episodes, and mortality were
performed using the intention-to-treat (ITT) principle.
Comparisons between the treatment groups were per-
formed with the Mann–Whitney–Wilcoxon rank-sum test for
quantitative data. For qualitative data, the Fisher exact test was
used. Time-to-event data are reported as Kaplan–Meier esti-
mates, the log-rank test provided inference. Multivariate anal-
ysis of time to rebleeding and overall survival was performed
with stepwise Cox regression. In a ﬁrst step, univariate Cox
regression was performed for each potentially explanatory
variable, preselecting those with test score P values less than .1.
Therapy always was selected. Selected variables then were
tested in a stepwise regression procedure with P value criteria
of .1 for inclusion and exclusion of explanatory variables into
the model. SAS software version 9.2 was used.
Ethics
The study protocol, informed consent form, and any addi-
tional related documents were approved by the ethics com-
mittee of the Medical Faculty of the University of Bonn in
cooperation with the local ethics committees of the other cen-
ters. The study was in accordance with the revised Declaration
of Helsinki (October 2000), the German drug law as amended,and the International Conference on Harmonization of Tech-
nical Requirements for Registration of Pharmaceuticals for
Human Use Good Clinical Practice (1996).
Results
Recruitment and Randomization
Of a total of 836 patients assessed for eligibility, 187
(22%) patients were randomized (Supplementary Appendix
and Supplementary Figure 1). Important reasons for
exclusion were refusal, ambiguous bleeding history,
assumed bleeding from gastric and other nonesophageal
varices, concomitant malignancy, or laboratory values that
did not match the inclusion criteria. The required number of
patients was recruited by 10 centers distributed throughout
Germany. Ninety-two patients were allocated to the TIPS
group A and 95 patients were allocated to the pharmaco-
logic/ligation group B. The ﬁrst patient was randomized in
June 2006 and the last patient was randomized in
September 2012. The study was closed in June 2013.
Baseline Characteristics and Progress of the
Randomized Groups
The ﬂow of patients is shown in Supplementary
Appendix. In the end, 185 patients were available for the
intention-to-treat analysis (104 patients in stratum I and
81 patients in stratum II) and 169 patients were available
for the per-protocol analysis.
The baseline characteristics, whether compared on an
intention-to-treat or per-protocol basis, were balanced
(Table 1).
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TIPS placement at a median of 4 days after randomiza-
tion achieved an average decrease of portal pressure
gradient (PPG) of 50% (22 ± 6 mm Hg to 11 ± 5 mm Hg).
In 43% of the patients, PPG was reduced to less than 10
mm Hg. In the remaining patients, the PPG averaged
14.0 ± 4 mm Hg after TIPS. The PPG reduction to less than
12 mm Hg was achieved in 61% of patients. In group B, 19
patients received no second HVPG measurement owing to
withdrawal (Supplementary Appendix) or rebleeding before
the second HVPG measurement (n ¼ 5). Thus, 76 patients
(80%) from group B received 2 HVPG measurements with
32 (42%) responders and 44 (58%) nonresponders, who
were switched to ligation. In the responders, HVPG
decreased on average by 29%, whereas the nonresponders
showed only a slight decrease of 5% (Table 2). Changes in
pulse rate, systemic blood pressure, and HVPG before and
after medical treatment are shown in Table 2.CLFollow-Up Evaluation: Primary and Secondary
Outcomes
Regarding the primary end point of rebleeding, the me-
dian follow-up period was 2.48 years (range, 0–6.97 y) in
group A and 1.32 years (range, 0–6.44 y) in group B. During
that time, 7 patients in group A and 23 patients in group B
showed signiﬁcant variceal bleeding (primary end point).
The difference, predominantly caused by an effect in stra-
tum I, was signiﬁcant (ITT and per-protocol-treatment, P ¼
.002) (Figure 1 and Supplementary Figure 2). In 6 patients
from group B (26% of the events in this group), variceal
rebleeding occurred before the hemodynamic response
could be assessed. The 2-year rebleeding rate was 7%
(cTIPS) vs 26% (medical prophylaxis) (hazard ratio, 0.28;
95% conﬁdence interval, 0.12–0.66; P ¼ .002). Time toTable 2.Hemodynamic Parameters at Baseline and
After Application of Propranolol and Isosorbide-
5-Mononitrate for Two Weeks in Group B Patients,
Who Received Two HVPG Measurements
Responder
(n ¼ 32)
Nonresponder
(n ¼ 44)
Propranolol dosage, mg/day 149 ± 73 125 ± 53
Pulse/min baseline 79 ± 14 79 ± 12
Pulse/min day 14 66 ± 12 62 ± 8
Baseline BP
(systolic/diastolic), mm Hg
123 ± 21/71 ± 10 121 ± 19/70 ± 9
Day 14 BP
(systolic/diastolic), mm Hg
118 ± 19/69 ± 10 118 ± 15/71 ± 10
Baseline HVPG, mm Hg 21 ± 6 20 ± 6
Day 14 HVPG, mm Hg 15 ± 5 19 ± 5
NOTE. Propranolol dosage (P ¼ .12) as well as baseline he-
modynamic parameters were not signiﬁcantly different be-
tween groups. HVPG decreased signiﬁcantly in responders
(P < .0001) and nonresponders (P < .013), whereas the
change of systemic blood pressure (baseline vs day 14) was
not signiﬁcant.
BP, systemic arterial blood pressure.death and time to rebleeding did not differ in group A
patients between those with PPG less than or greater than
12 mm Hg after TIPS placement (P ¼ .836 and .479,
respectively). Per-protocol analysis of group B only showed
that rebleeding events were lower (P ¼ .06) in the
responder group (2-year rate, 18%) than in the nonre-
sponder group (n ¼ 44) and early rebleeders (n ¼ 5)
combined together (2-year rate, 31%) (Supplementary
Figure 3A).
Fifteen patients in group B received TIPS as a result of
refractory ascites (n ¼ 9), bleeding (n ¼ 4), portal vein
thrombosis (n ¼ 1), or lack of compliance (n ¼ 1) at a
median of 2 months (range, 0.3–36 mo) after randomization.
The average baseline Child–Pugh score of these patients was
higher (7.9 ± 1.9; P ¼ .02) than in the remaining group B
patients (6.8 ± 1.6). HVPG (19.5 ± 7.3 vs 20.6 ± 5.9 mm Hg)
did not differ signiﬁcantly. Of these TIPS patients, 73%
(11 of 15) were hemodynamic nonresponders. They were
kept in group B (ITT analysis). Censoring of these patients
at the time of TIPS placement did not change our ﬁndings
(log-rank P ¼ .001 for rebleeding and P ¼ .965 for death).
Twenty-seven patients in group A and 25 patients in
group B died (Table 3). The majority of deaths were caused
by liver failure or infection. One patient died after the TIPS
procedure, and in 3 group B patients variceal hemorrhage
was the cause of death. There were no signiﬁcant differ-
ences in the survival curves within a median follow-up
period of 3.20 years (range, 0–6.97 y) (group A) and 1.96
years (range, 0–6.97 y) (group B), regardless of whether
analyzed by intention-to-treat, per-protocol, or per-stratum
(Figure 2 and Supplementary Figure 4).
Five patients in group A received a liver transplantation
after a median of 7 months (range, 6–66 mo) and 4 patients
in group B after 11 months (range, 3–48 mo) with 1 peri-
operative death.
When analyzing the results with respect to combined
end points (death or rebleeding), the advantage in favor of
group A persisted (Supplementary Figure 5).
Multivariate analysis including the parameters treat-
ment group, international normalized ratio, aminotransfer-
ases, bilirubin, albumin, creatinine, sodium, portal pressure,
ascites, and stratum showed that allocation to group B,
bilirubin, albumin, and creatinine were associated inde-
pendently with rebleeding. Independent risk factors for
death were albumin, portal pressure, and stratum I
(Supplementary Tables 1 and 2).
In group B, the survival curve of medical responders
(n ¼ 32) was similar to those of nonresponders
(Supplementary Figure 3B).Safety: Follow-Up Evaluation of Laboratory
Values and Adverse Events
A slight increase of bilirubin level and the international
normalized ratio was observed after TIPS in patients in
group A. By contrast, creatinine values trended downward
(Supplementary Figures 6–8).
Overall, there were 773 adverse events, classiﬁed as
serious according to the International Conference on
Figure 1. Kaplan–Meier plot (intention-to-treat) comparing time to rebleeding from varices in (A) all patients, and in (B) patients
who were randomized 6–21 days after bleeding (104 patients stratum I), or (C) more than 3 weeks after bleeding (81 patients
stratum II). Group A: TIPS, continuous blue line; group B: medical prophylaxis with change to ligation in hemodynamic
nonresponders, dashed red line. The hazard ratio for bleeding in group A was 0.28 (95% conﬁdence interval, 0.12–0.66) for all
patients, 0.22 (95% conﬁdence interval, 0.072–0.64) in stratum I, and 0.50 (95% conﬁdence interval, 0.12–1.99) in stratum II.
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287 times (71 patients) in group A and 196 times (64 pa-
tients) in group B (Supplementary Table 3). Patients in
group A had to be treated more often for nervous system
disorders (mainly overt encephalopathy, 2-year rate, 18%
vs 8%; hazard ratio, 2.4; 95% conﬁdence interval, 0.99–5.9,
P ¼ .05) (Figure 3), cardiac disorders, investigations, and
medical procedures (mainly TIPS revisions) (Supplementary
Figure 9) than patients in group B, who had more gastro-
intestinal disorders (mainly owing to bleeding and ligation)
and hepatobiliary disorders (mainly associated with asci-
tes). With respect to encephalopathy, there was no differ-
ence between patients with portal pressure gradients less
than or greater than 12 mm Hg after TIPS placement
(P ¼ .939). Later TIPS interventions were necessary in 8%
of the patients with PPG less than 10 mm Hg and in 29%
of patients with PPG of 10 mm Hg or greater as assessed
immediately after insertion.
Analysis of safety with respect to groups and the
2 strata showed no major imbalance. In particular, TIPS
induced no harm in stratum II (Supplementary Table 3).
Serious adverse events occurred slightly more often in
stratum I.
Quality of Life
The SF-36 summary scores29 concerning physical or
mental components showed no difference between groupsat baseline and during follow-up evaluation (Supplementary
Figures 10 and 11).
Discussion
This was a large randomized study comparing TIPS with
a primary pharmacologic approach for the prevention of
rebleeding from esophageal varices in patients with moder-
ately decompensated cirrhosis. It shows the superiority of an
elective 8-mm cTIPS for the prevention of rebleeding. How-
ever, this had no effect on survival or quality of life.
There were more adverse events in the TIPS group, but
the percentage of patients with serious adverse events was
only slightly higher in this group. The overt encephalopathy
rate was comparatively low, probably because of the small
TIPS diameter.
The primary aim of the trial was the comparison be-
tween TIPS and hemodynamically controlled pharmacologic
treatment. Although TIPS reduced portal pressure on
average by 50%, propranolol and nitrates achieved a mean
reduction of 15% after 2 weeks, similar to the value of 16%
calculated in a recent meta-analysis.30 Although NSBBs plus
nitrates decrease portal pressure only moderately, it is an
effective regimen for rebleeding prophylaxis with a possible
beneﬁcial effect on survival.6,9 Sufﬁcient portal pressure
reduction prevents rebleeding, but nonresponders hardly
are protected.17–19,26 Forty-two percent of our patients in
whom 2 measurements were possible responded
adequately. This is well within the range assessed by a
Table 3.Causes of Death: Group A: TIPS, Group B: Drugs/
Ligation
Group A
27/90 (30%)
Group B
25/95 (26%)
Liver failure 11 9
Infection 6 8
Hepatocellular carcinoma 1 2
Bleeding 1 3
TIPS complication 1 -
Liver transplantation - 1
Others 7a -
Unknown - 2b
aKidney failure, gallbladder cancer, leukemia, stroke, bleeding
peptic ulcer, and cardiac arrhythmia.
bBoth patients died at home, 1 in Turkey, the other was found
by police together with bottles of alcoholic beverages.
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rate in these patients did not differ signiﬁcantly from the
TIPS group at 2 years of follow-up evaluation (18% vs 7%;
P ¼ .15). Carvedilol, a NSBB with additional a1-
adrenoceptor–blocking properties, showed a better hemo-
dynamic response rate,30,31 but there are no randomized
end point trials comparing this drug with propranolol.
Thus, it probably is too early to favor this speciﬁc b-blocker
for medical rebleeding prophylaxis.Figure 2. Kaplan–Meier plot (intention-to-treat) comparing time
(medical prophylaxis and change to ligation in hemodynamic n
(randomization 6–21 days after bleeding, 104 patients), and (C) s
The hazard ratio for death in group A was 0.92 (95% conﬁden
interval, 0.47–1.70) in stratum I, and 1.05 (95% conﬁdence inteOur study design showed a previously addressed prob-
lem.19,27 Patients with sole pharmacologic treatment pre-
sented early rebleeding before hemodynamic analysis. The
optimal time frame to assess the response is ill deﬁned. We
chose 14 days because we assumed patients to be in a good
steady state after this period. Whether intravenous infusion
of a test dose of propranolol is a valid prognostic substi-
tute32,33 remains to be investigated in randomized trials
with clinical end points.
Patients who showed no response were switched to
ligation only. This has the advantage that patients are no
longer at risk for side effects of medical therapy.34–36 It has
repeatedly been argued that there are further beneﬁcial
effects of NSBBs beyond decreasing portal pressure.37 We
cannot refute this argument. We found that our patients
who received only ligation showed a slightly higher
rebleeding rate than the medical responders despite later
TIPS placement in one fourth of the ligated patients. How-
ever, survival was not different between these groups
(Supplementary Figure 3). Thus, once response to therapy
has been assessed either ligation alone or drugs alone are
possible options as a ﬁrst step for elective rebleeding
prophylaxis.
Independent factors associated with rebleeding were
allocation to group B, bilirubin, and albumin. This conﬁrms
that rebleeding is associated with parameters of the Child
classiﬁcation. Interestingly, low baseline creatinine level
also correlated with more rebleeding events. This wasto death in group A (TIPS, continuous blue line) with group B
onresponders, dashed red line). (A) All patients, (B) stratum I
tratum II (randomization >3 weeks after bleeding, 81 patients).
ce interval, 0.53–1.59) for all patients, 0.90 (95% conﬁdence
rval, 0.35–3.13) in stratum II.
Figure 3. Kaplan–Meier
plot comparing overt en-
cephalopathy in patients
receiving TIPS (group A,
continuous blue line) or
medical treatment with
change to ligation in he-
modynamic nonresponders
(group B, dashed red line).
The hazard ratio for en-
cephalopathy in group A
was 2.4 (95% conﬁdence
interval, 0.99–5.99), 18% at
2 years in group A and 8%
in group B.
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creatinine level have more cachexia and are more prone to
rebleed. Low albumin level, a short time after the index
bleeding, and high portal pressure were independent pa-
rameters associated with death. This underlines earlier
ﬁndings that assessment of portal pressure adds indepen-
dent information for prediction of survival time in patients
with cirrhosis.15,38 However, interventions reducing portal
pressure failed to improve survival in most controlled trials,
probably because the intrahepatic inﬂammatory cascades of
chronic liver disease are not targeted by this approach.
Rebleeding did not correlate with the baseline portal pres-
sure. This can be explained by the fact that all patients
received interventions to decrease portal blood pressure,
which might obscure its role in the natural history of vari-
ceal bleeding. Low albumin level was the only independent
Child parameter associated with death.
We selected patients with compensated liver function,
explaining a 2-year survival rate of 76% (group A) and 81%
(group B). The 5-year survival rate was 65% (group A) vs
54% (group B). Thus, both approaches were equal. Causes
of deaths and the rate of patients receiving liver trans-
plantation also were very similar. Under these conditions,
adverse events and quality of life should be compared. By
using the SF-36 health survey we found no difference be-
tween groups or a major change over time. The TIPS group
had more adverse events mainly owing to problems of the
central nervous system (often hepatic encephalopathy) or
TIPS revisions, whereas the conservative group experienced
more adverse events caused by ascites, variceal banding, or
bleeding.
We opted for placement of an 8-mm cTIPS. It showed
adequate bleeding prophylaxis and a low overt encepha-
lopathy rate. In this respect and in respect to hemodynamic
control as well as the severity of liver disease our trial
differed from another study that found a rather highcumulative complication rate in the 8-mm stent group as
compared with 10-mm cTIPS.39 Overall, the PPG was halved
by TIPS insertion despite the fact that in only 40% of the
patients the PPG was reduced to less than 10 mm Hg. This
might explain invasive TIPS revision over time in nearly one
third of these individuals as compared with 8% in patients
with a PPG less than 10 mm Hg after TIPS. Our approach
probably is the best choice to lessen encephalopathy epi-
sodes. A PPG gradient less than 12 mm Hg is believed to be
associated with complete protection from bleeding. This
was achieved in 61% of TIPS patients.
It has been shown that the risk of rebleeding and death
decreases with an increasing time interval between index
bleeding and intervention.40 We met this selection phe-
nomenon by stratifying patients (see the Materials and
Methods section). The most relevant effect was conﬁned to
stratum I (patients randomized within 6–21 days after the
index bleeding who had received TIPS at a median of 15
days after the bleeding event), suggesting and conﬁrming
that the effect of TIPS probably is most pronounced when
placed in close temporal relation to bleeding.12 If the
bleeding-free interval surpasses 6 weeks then the rebleed-
ing risk may be close to the situation in primary prevention.
In stratum II, 75% of our patients (77% in group A and 74%
in group B) bled more than 42 days before randomization
and the median time between the index bleeding and TIPS
insertion in stratum II was 3.6 months. Although it can be
argued that TIPS is harmful in this situation we found
neither an excess mortality induced by TIPS nor a higher
ratio of adverse events (group A to B) in stratum II. A slight
trend toward less rebleedings remained in the TIPS group of
stratum II.
Some patients in group B eventually received TIPS (16%
in our trial) with refractory ascites as the main indication.
Most of these patients belonged to the hemodynamic non-
responders. Censoring of these group B patients at the time
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Kaplan–Meier plots.
What new information does our trial contribute to the
numerous other studies on TIPS insertion for prophylaxis of
rebleeding? First, small-diameter cTIPS is effective in pa-
tients with moderately decompensated cirrhosis. Second,
although hemodynamic responders are well treated with
drugs only, we need the information on drug response early
on. This problem has not been solved to date. Third, TIPS
loses its superiority in the prevention of rebleeding if placed
more than 3 weeks after the index bleeding, a possible se-
lection phenomenon.
Our trial had some limitations. Only 22% of the screened
patients were randomized; not all group B patients received
2 HVPG measurements; the time interval between the index
bleeding and randomization had a large scatter; and the
treatment approach in group B was more heterogeneous.
Conclusions
Although according to our study small-diameter cTIPS is
not mandatory as ﬁrst-line elective rebleeding prevention, it
is more simple and effective than primary medical portal
pressure reduction with hemodynamic control. The latter
approach requires further step-by-step therapy in the ma-
jority of patients. The percentage of patients with adverse
events, as well as survival and quality of life, appear to be
quite balanced between both approaches.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Appendix. Chart showing the design of the study and the ﬂow of patients. Please note that 5 of the 81 per-
protocol group B patients had a bleeding end point before the second HVPG measurement. Within the ﬁrst 24 months after
randomization out of the per-protocol patients in group A, 6 patients were lost to follow-up evaluation before study end and
censored, 2 patients because of transfer to another hospital for malignant disease (at months 5 and 12) and 4 patients because
of withdrawal of consent for further follow-up evaluation (at months 1, 6, 7, and 12). Of the per-protocol patients in group B,
4 patients were lost before the end of study and censored, 1 patient was lost because of transfer to another hospital (at month
12), and 3 patients because of withdrawal of consent for further follow-up evaluation (at months 3, 3, and 6). The speciﬁc
reasons why patients were not eligible for randomization are shown in Supplementary Figure 1.
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